Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,411 across all filing types
Latest filing 2025-12-15 Transaction in Own Shar…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is a formal declaration of share buyback transactions ('Déclaration des transactions sur actions propres') by Sanofi. It provides a detailed breakdown of daily aggregated volumes and individual transaction records, including dates, prices, and quantities, in compliance with market regulations (MAR art.5). This fits the definition of 'Transaction in Own Shares' (POS).
2025-12-15 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure by Sanofi regarding the purchase of its own shares (share buyback) over a specific period (08 December 2025 to 12 December 2025). It includes aggregated daily data and a detailed transaction log, which is characteristic of 'Transaction in Own Shares' filings. This aligns perfectly with the definition for code POS.
2025-12-15 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC to provide current information. It references press releases attached as exhibits, which are updates on regulatory submissions and clinical progress. The document is short (1505 characters) and primarily serves as a filing to report these press releases rather than containing detailed financial data or comprehensive reports. It does not contain financial statements or detailed analysis, nor is it an announcement of voting results, management changes, or other specific categories. Given the nature of Form 6-K filings as periodic regulatory updates for foreign issuers, and the lack of detailed financial or management content, the appropriate classification is Regulatory Filings (RNS).
2025-12-15 English
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing the results of a clinical trial (PERSEUS phase 3 study) for the drug tolebrutinib. It details the failure to meet primary endpoints, the company's decision not to pursue regulatory registration for this specific indication, and includes a section on financial considerations regarding impairment testing. As this is a corporate announcement regarding operational/clinical updates and does not fit into specific categories like earnings releases or financial reports, it is classified as a general regulatory filing/announcement.
2025-12-15 English
Communiqué de presse : Sanofi fait le point sur le tolébrutinib dans la sclérose en plaques primaire progressive
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing the results of a Phase 3 clinical trial (PERSEUS) for the drug tolebrutinib. It details the failure to meet the primary endpoint, the company's decision to discontinue regulatory registration for this specific indication, and the financial implications (impairment test). As this is a corporate announcement regarding clinical trial results and business strategy, it falls under the category of general regulatory announcements/filings that do not fit into more specific categories like earnings releases or annual reports.
2025-12-15 French
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi regarding a regulatory update on the tolebrutinib drug submission with the FDA. It details a delay in the regulatory decision process. This type of announcement, which provides updates on regulatory status, clinical trials, or drug development milestones, is classified as a Regulatory Filing (RNS) as it does not fit into specific categories like M&A, dividends, or financial reports.
2025-12-15 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.